Coherus Oncology, Inc. Common Stock
CHRSCoherus BioSciences, Inc. is a biotechnology company focused on developing and commercializing biosimilar and biologic therapies. The company aims to provide affordable alternatives to existing biologic treatments in areas such as oncology, immunology, and ophthalmology. Coherus focuses on advanced biologic products and has a portfolio that includes biosimilars for popular reference drugs.
Company News
Coherus Oncology announced the appointment of Arvind Sood as Chief Strategy and Corporate Affairs Officer, focusing on advancing innovative cancer therapeutics and driving revenues for LOQTORZI®.
Coherus BioSciences announced it will repurchase $170 million of its convertible notes and divest its UDENYCA franchise to Intas Pharmaceuticals. The company plans to repurchase the remaining $60 million of convertible notes after the divestiture closes.
The hepatic tumor market is driven by the increasing incidence of liver cancer, advancements in treatment options, and the growing emphasis on personalized medicine and combination therapies. The pipeline comprises 75+ companies working on 75+ pipeline therapies, with several promising candidates in different phases of clinical trials.
– Transaction aligns with Coherus’ strategic focus on oncology – – Transaction aligns with Coherus’ strategic focus on oncology –
